[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![SentinelFlash Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1873821816604565505.png) StockSentinel [@SentinelFlash](/creator/twitter/SentinelFlash) on x XX followers
Created: 2025-07-16 19:01:07 UTC

$PRCT: PROCEPT BioRobotics is shaking up urologic surgery with rapid growth and a $20B+ market opportunity, but profitability is still on the horizon. Its Aquablation tech is gaining traction, with recurring revenues and analyst optimism fueling the story. Shares have pulled back, creating a potential entry point, yet execution and reimbursement risks remain. Will PROCEPT’s bold innovation become the new standard of care—or will competition and valuation risks hold it back?


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945559337788731517/c:line.svg)

**Related Topics**
[stocks](/topic/stocks)
[$20b](/topic/$20b)
[$prct](/topic/$prct)

[Post Link](https://x.com/SentinelFlash/status/1945559337788731517)